nim811 is a form of treatment for patients with the hepatitis c virus (hcv). studies indicate a strong relationship between a treatments cyclophilin binding affinity and suppression of hcv activity. nim811 is also being studied as a potential treatment to genetic muscular diseases such as ullrich congenital muscular dystrophy (ucmd) and bethlem myopathy (bm) disease, diseases altering the genes for collagen vi production.